Lundbeck to acquire Ovation Pharmaceuticals
Denmark-based pharmaceutical company H Lundbeck and Ovation Pharmaceuticals, a specialty pharmaceutical company, have entered into a definitive transaction agreement under which Lundbeck, through its wholly owned subsidiary Lundbeck Inc will acquire Ovation in an all cash transaction valuing Ovation at up to $900 million.
Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.